| Yuli Fradkin, MD | |
|
94 Valley Rd Fl 2, Montclair, NJ 07042-2211 | |
| (646) 685-9836 | |
| Not Available |
| Full Name | Yuli Fradkin |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 30 Years |
| Location | 94 Valley Rd Fl 2, Montclair, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255589461 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yuli Fradkin Md Llc | 0648596148 | 3 |
| Yuli Fradkin Md Llc | 0648596148 | 3 |
News Archive
In the current issue of PLOS Genetics, Michigan State University genetic scientists have begun to understand how the rest of the genome interacts with such mutations to cause the differences we see among individuals.
Even if you could get more RAM for your brain, the extra storage probably wouldn't make it easier for you to find where you left your car keys.
VHA Inc., the national network, has selected RadarFind, a TeleTracking company, to provide its real-time locating distributed sensor network to VHA's 1,400 member hospitals to track equipment, patients and staff for improved operational efficiency and patient care.
Genia Technologies, Inc. today announced that the company, as part of a research consortium with Columbia University and Harvard Medical School, received a Revolutionary Genome Sequencing Technologies – The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH).
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 4 days ago
| Entity Name | Westchester Medical Center Advanced Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912131392 PECOS PAC ID: 3173660776 Enrollment ID: O20091031000042 |
News Archive
In the current issue of PLOS Genetics, Michigan State University genetic scientists have begun to understand how the rest of the genome interacts with such mutations to cause the differences we see among individuals.
Even if you could get more RAM for your brain, the extra storage probably wouldn't make it easier for you to find where you left your car keys.
VHA Inc., the national network, has selected RadarFind, a TeleTracking company, to provide its real-time locating distributed sensor network to VHA's 1,400 member hospitals to track equipment, patients and staff for improved operational efficiency and patient care.
Genia Technologies, Inc. today announced that the company, as part of a research consortium with Columbia University and Harvard Medical School, received a Revolutionary Genome Sequencing Technologies – The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH).
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 4 days ago
| Entity Name | Coney Island Medical Practice Plan, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386951762 PECOS PAC ID: 5496944803 Enrollment ID: O20110114000660 |
News Archive
In the current issue of PLOS Genetics, Michigan State University genetic scientists have begun to understand how the rest of the genome interacts with such mutations to cause the differences we see among individuals.
Even if you could get more RAM for your brain, the extra storage probably wouldn't make it easier for you to find where you left your car keys.
VHA Inc., the national network, has selected RadarFind, a TeleTracking company, to provide its real-time locating distributed sensor network to VHA's 1,400 member hospitals to track equipment, patients and staff for improved operational efficiency and patient care.
Genia Technologies, Inc. today announced that the company, as part of a research consortium with Columbia University and Harvard Medical School, received a Revolutionary Genome Sequencing Technologies – The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH).
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 4 days ago
| Entity Name | Yuli Fradkin Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972908960 PECOS PAC ID: 0648596148 Enrollment ID: O20200217004155 |
News Archive
In the current issue of PLOS Genetics, Michigan State University genetic scientists have begun to understand how the rest of the genome interacts with such mutations to cause the differences we see among individuals.
Even if you could get more RAM for your brain, the extra storage probably wouldn't make it easier for you to find where you left your car keys.
VHA Inc., the national network, has selected RadarFind, a TeleTracking company, to provide its real-time locating distributed sensor network to VHA's 1,400 member hospitals to track equipment, patients and staff for improved operational efficiency and patient care.
Genia Technologies, Inc. today announced that the company, as part of a research consortium with Columbia University and Harvard Medical School, received a Revolutionary Genome Sequencing Technologies – The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH).
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yuli Fradkin, MD 39 James St, Montclair, NJ 07042-2913 Ph: (646) 685-9836 | Yuli Fradkin, MD 94 Valley Rd Fl 2, Montclair, NJ 07042-2211 Ph: (646) 685-9836 |
News Archive
In the current issue of PLOS Genetics, Michigan State University genetic scientists have begun to understand how the rest of the genome interacts with such mutations to cause the differences we see among individuals.
Even if you could get more RAM for your brain, the extra storage probably wouldn't make it easier for you to find where you left your car keys.
VHA Inc., the national network, has selected RadarFind, a TeleTracking company, to provide its real-time locating distributed sensor network to VHA's 1,400 member hospitals to track equipment, patients and staff for improved operational efficiency and patient care.
Genia Technologies, Inc. today announced that the company, as part of a research consortium with Columbia University and Harvard Medical School, received a Revolutionary Genome Sequencing Technologies – The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH).
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 4 days ago
Dr. David Blady, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 127 Pine St, Montclair, NJ 07042 Phone: 973-743-9555 | |
Dr. John Cooke, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 516 Bloomfield Ave, Suite 4, Montclair, NJ 07042 Phone: 973-509-1500 Fax: 973-509-1919 | |
Dr. Bruce P Friedman, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 207 Inwood Ave, Montclair, NJ 07043 Phone: 973-509-8400 Fax: 973-337-5097 | |
Dr. Laurence Michael Westreich, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 202 Bellevue Ave, Side Entrance, Montclair, NJ 07043 Phone: 973-509-1444 | |
Marie R Badaracco-apolito, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 88 Norwood Ave, Montclair, NJ 07043 Phone: 973-783-5033 Fax: 973-746-2604 | |
Dr. Paul Vincent Kennedy, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 117 Watchung Ave, 2nd Floor, Montclair, NJ 07043 Phone: 973-783-2984 Fax: 973-783-5074 | |
Dr. Edward A Latimer, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 24 Portland Pl, Montclair, NJ 07042 Phone: 973-744-1880 Fax: 973-746-9575 |